| abstract |
An insulin secretion promoter that alleviates side effects, such as acceleration of obesity and arteriosclerosis, and minimizes any strain on pancreatic .beta. cells so as not to be detrimental to insulin secretion capability. There is provided a promoter of insulin secretion with glucose dependence responsive to high blood sugar, comprising as an active ingredient a substance having the activity of PPAR.delta. activation. This insulin secretion promoter simultaneously exhibits anti-obesity activity, serum cholesterol reducing activity useful for the treatment and prevention of arteriosclerosis, etc. and insulin resistance ameliorating activity. |